AI-generated summary
In this single-center cohort study of 86 vitiligo patients, the authors report that antinuclear antibody positivity was not associated with significant differences in overall efficacy or safety of 308-nm excimer light therapy. ANA-positive facial and neck lesions more often reached moderate repigmentation but were less likely to reach excellent repigmentation. The authors note the impact of low-titer ANA may be limited.
- Participants
- 86
- Who or what was studied
- Patients with vitiligo treated with 308-nm excimer light therapy, stratified by antinuclear antibody status
- Wavelengths
- 308 nm
- Limits stated in the abstract
- The abstract describes a single-center cohort study, and the authors conclude the impact of low-titer ANA may be limited, leaving the certainty of the findings unclear.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.